Key result
MMP-8 deficiency protects against lethal hepatitis by reducing liver cell death and leukocyte influx.
Answers are grounded in this paper and cite their sources.
Demonstrates that matrix metalloproteinase-8 deficiency protects mice from TNF-induced lethal hepatitis, suggesting a potential therapeutic target for acute liver failure.
Acute fulminant liver failure is a serious worldwide health problem. Despite maximal supportive intensive care treatment, the disease offers a poor prognosis, with mortality rates of >80%. We have previously shown that a broad-spectrum inhibitor of matrix metalloproteinases (MMPs) confers complete protection in a mouse model of TNF-induced lethal hepatitis, thereby suggesting the possibility of protecting cancer patients against the deleterious side effects of TNF therapy. In our search for the individual matrix metalloproteinases involved, we found that the recently generated MMP-8-deficient mice are significantly protected against TNF-induced acute hepatitis. In contrast to their wild-type counterparts, MMP-8-null mice display very little hepatocyte necrosis and apoptosis, resulting in a much better survival outcome. We found that these animals clearly display impaired leukocyte influx into the liver and no release of the neutrophil-specific, LPS-induced CXC chemokine. Our findings provide evidence that MMP-8 plays an essential role in acute liver failure and might be a promising new target for the treatment for this illness.
No takes yet. Share an insight, caveat, or question.
Lint et al. (2005) studied TNF-induced lethal hepatitis / acute liver failure. Matrix metalloproteinase-8 (MMP-8) deficiency vs. Wild-type mice was evaluated on Survival outcome, hepatocyte necrosis and apoptosis in TNF-induced acute hepatitis. MMP-8 deficiency in mice significantly protected against TNF-induced lethal hepatitis, reducing hepatocyte necrosis, apoptosis, and leukocyte influx while improving survival.
Synapse has enriched 10 related papers. Consider them for comparative context: